Introduction
============

COPD is characterized by persistent airflow limitation.[@b1-copd-11-2035],[@b2-copd-11-2035] Inhaled β~2~-agonists and antimuscarinics have become central to the management of patients with COPD, as they improve lung function.[@b2-copd-11-2035] Improvements in exercise tolerance and quality of life, and reductions in COPD symptoms including exacerbations have also been demonstrated with these treatments.[@b2-copd-11-2035] Long-acting bronchodilators are used as regular maintenance therapies in patients with moderate-to-severe COPD, while short-acting bronchodilators are generally used as required to provide symptomatic relief.[@b2-copd-11-2035]

Despite little evidence to suggest a bimodal distribution of bronchodilator response with two distinct groups of responders and nonresponders,[@b3-copd-11-2035],[@b4-copd-11-2035] the paradigm of the reversible and nonreversible COPD phenotype has been widely applied to classify patients in clinical trials.[@b5-copd-11-2035]--[@b8-copd-11-2035] However, bronchodilator responsiveness may be considered a continuous variable,[@b9-copd-11-2035] with the effect of bronchodilators on lung function varying substantially between patients.[@b2-copd-11-2035],[@b10-copd-11-2035] The 200 mL cut-off point used to establish reversibility[@b6-copd-11-2035] is close to the mean forced expiratory volume in 1 second (FEV~1~) response of patients with COPD to albuterol (eg, Buhl et al reported mean FEV~1~ values of 164--177 mL in a population of 5,162 patients[@b11-copd-11-2035]), and therefore, the categorization of a patient as reversible or not reversible may not be consistent over time.[@b9-copd-11-2035],[@b12-copd-11-2035] Based on these findings, Calverley et al recommended that the dichotomized outcome of classifying patients as reversible or not reversible should be abandoned.[@b9-copd-11-2035]

As a result of the issues surrounding bronchodilator responsiveness, the relationship between baseline reversibility and clinical outcomes or diagnoses has been questioned.[@b3-copd-11-2035],[@b6-copd-11-2035],[@b12-copd-11-2035] For example, in an analysis of the Understanding Potential Long-term Improvements in Function with Tiotropium (UPLIFT) study, the authors concluded that baseline bronchodilator responsiveness to ipratropium and albuterol, when assessed using three distinct categories, was not predictive of clinically important outcomes with tiotropium.[@b6-copd-11-2035] In another study, when lack of reversibility to bronchodilators was used as a diagnostic marker for COPD, there was an underdiagnosis of COPD.[@b3-copd-11-2035] It is now accepted that bronchodilator reversibility should not be included in diagnostic criteria for COPD.[@b2-copd-11-2035] However, bronchodilator reversibility is still measured in many research studies and clinical trials to characterize patients, and is used routinely in clinical practice as the post-bronchodilator FEV~1~ is used for diagnosis of COPD.[@b3-copd-11-2035],[@b6-copd-11-2035]--[@b8-copd-11-2035],[@b13-copd-11-2035]

We recently reported that the free combination of the short-acting bronchodilators albuterol (a β~2~-agonist) and ipratropium (a muscarinic antagonist) led to lower day-to-day variability in FEV~1~ compared with either monotherapy.[@b14-copd-11-2035] Here, we report a novel post hoc analysis of data from this clinical study, investigating the reproducibility of treatment response to a short-acting bronchodilator by considering reversibility as a continuous variable, rather than "reversible" or "nonreversible".

Methods
=======

Study design
------------

This was a post hoc analysis of a 4-week, randomized, open-label, two-period crossover study performed at two study centers specializing in spirometry (one in the UK, one in the US), between July 2012 and February 2013 (NCT01691482; GSK study number DB2114956).[@b14-copd-11-2035] Patients were ≥40 years of age, were current or former smokers with a smoking history of ≥10 pack-years, had a previous physician diagnosis of COPD,[@b1-copd-11-2035] had a post-albuterol FEV~1~/forced vital capacity ratio \<0.70, and a post-albuterol FEV~1~ of ≥30% and ≤70% of predicted normal. Concomitant use of inhaled corticosteroids at a stable dose was permitted. Patients with a current diagnosis of asthma or any clinical significant uncontrolled disease were excluded.[@b14-copd-11-2035]

Patients were randomized 1:1 to receive albuterol (GlaxoSmithKline, Middlesex, UK) via metered dose inhaler (doses: UK =4×100 μg/puff; US =4×90 μg/puff), followed by ipratropium 1 hour later (4×20 μg/puff; Boehringer Ingelheim, Ingelheim, Germany) or vice versa, during treatment Period 1 (10--14 days). The order of treatments was then reversed during treatment Period 2. Placebo was administered on Day 4 in both study periods. There was no washout stage between Periods 1 and 2.[@b14-copd-11-2035] At each visit (except for Day 4 of each study period \[Visits 5 and 15\]), pre-dose spirometry was performed, followed by the administration of either albuterol or ipratropium. Spirometry was repeated 1 hour after administration ([Figure S1](#SD1-copd-11-2035){ref-type="supplementary-material"}). On Day 4 of each study period, spirometry readings were taken at approximately the same times (ie, at 0 and 1 hour). At each study visit, patients were asked to refrain from smoking for 1 hour prior to the first pulmonary function test and throughout the study visit, until after the last spirometry test had been performed.[@b14-copd-11-2035] The analyses detailed in this study were completed for both albuterol and ipratropium. The study protocol and any amendments were reviewed and approved by a national, regional, or investigational center ethics committee or institutional review board (Manchester Evaluation Unit, Manchester, UK: D2012-2166-E02-UK; Chesapeake institutional review board, SC, USA: PRO0007141). Written informed consent was obtained from each patient prior to initiation of any study procedures.

Outcomes and assessments
------------------------

Full details on outcomes and assessments for the DB2114956 study have been previously published.[@b14-copd-11-2035] The post hoc analyses presented in this study focused on the bronchodilator treatment response in terms of FEV~1~, defined as the change in FEV~1~ at 1 hour (post-dose) from 0 hour (pre-dose) on each day. Initial exploratory post hoc analyses examined the correlation coefficient of FEV~1~ response between Day 1 and Day 10. The mean within-patient difference in FEV~1~ response (including the proportion of patients exhibiting differences of \<100, ≥100 to \<150, ≥150 to \<200, and ≥200 mL) between these days was also calculated. The correlation coefficient of bronchodilator treatment response on Day 1 and the mean treatment response on Days 5--10, for each individual patient, were also investigated. Additional post hoc analyses included the following: 1) the correlation coefficient of the mean treatment response for Days 1--2 and Days 1--3 with the mean response during Days 5--10, for each individual patient; and 2) the stability of each individual patient's status as reversible or nonreversible on Day 1 compared with Day 10. Reversibility was defined as an increase in FEV~1~ of ≥12% and ≥200 mL following administration of albuterol or ipratropium.

Statistical analyses
--------------------

Time-dependent bronchodilator responses to albuterol or ipratropium were assessed by correlation coefficient analyses. The pairwise linear correlation coefficients of FEV~1~ at pre-dose (0 hour) and 1 hour post-dose were computed by treatment and by day to assess the individual effect of albuterol or ipratropium over time. These post hoc analyses did not take study period into consideration.

The overall analysis population was defined as all patients who were randomized and completed pre- and post-bronchodilator assessments for at least 17 visits, with no more than 3 consecutive missing days. All programming was performed using SAS version 9 (SAS Institute Inc., Cary, NC, USA) and S-Plus version 7. (TIBCO Software Inc, CA, USA).

Results
=======

Overall, 70 patients were screened, 56 were randomized to treatment and received at least one dose of bronchodilator in the treatment period (intent-to-treat population), and 53 patients completed the study. One patient in the intent-to-treat population was excluded from the efficacy population due to missing study visits for more than 3 consecutive days; therefore, data from 55 patients were analyzed. Baseline characteristics of the patients have been previously published.[@b14-copd-11-2035] Briefly, patients had a mean age of 60.3 years (standard deviation \[SD\]: 7.42 years) and a mean predicted FEV~1~ post-albuterol at screening of 51.33% (SD: 9.87%). The mean FEV~1~ reversibility at the screening visit was 193 mL (SD: 188 mL), and the mean percentage reversibility was 19.54% (SD: 17.39%). Twenty-six (46%) patients were considered reversible (defined as an increase in FEV~1~ of ≥12% and ≥200 mL following administration of albuterol) at screening, and 30 (54%) were nonreversible.

The correlation coefficient of individual bronchodilator treatment response (change in FEV~1~ from 0 to 1 hour post-dose) to albuterol on Day 1 with that on Day 10 was 0.64 ([Figure 1](#f1-copd-11-2035){ref-type="fig"}). The mean response to albuterol was 261 mL on Day 1 and 237 mL on Day 10, with a mean within-patient difference (Day 1 vs Day 10) of 47 mL ([Table 1](#t1-copd-11-2035){ref-type="table"}). The mean response to ipratropium was 253 mL on Day 1 and 241 mL on Day 10, with a mean within-patient difference (Day 1 vs Day 10) of 27 mL ([Table 1](#t1-copd-11-2035){ref-type="table"}). There was wide variability in the mean FEV~1~ responses to both treatments, as demonstrated by the associated SD values ([Table 1](#t1-copd-11-2035){ref-type="table"}). Out of 53 patients who received albuterol on Day 1 and Day 10, 31 (58%) had a response to albuterol on Day 10 that was \<100 mL different to their response on Day 1; a similar proportion of patients (n=28; 52%) met this criterion for ipratropium at Day 10 ([Table 2](#t2-copd-11-2035){ref-type="table"}).

The correlation coefficient of bronchodilator treatment response on Day 1 and the mean of Days 5--10 was 0.78 (*P*\<0.001) and 0.76 (*P*\<0.001) for albuterol and ipratropium, respectively. The correlation coefficient of bronchodilator treatment response over the means of Days 1--2 (0.85 and 0.81 for albuterol and ipratropium, respectively) and Days 1--3 (0.88 and 0.84) with the means of Days 5--10 increased (compared with Day 1 and Days 5--10) for both bronchodilators.

At Day 10, 42 out of 53 (79%) patients receiving albuterol had not changed their reversibility status (defined as an increase in FEV~1~ of ≥12% and ≥200 mL following administration of albuterol or ipratropium) from Day 1 (reversible at both days: n=24 \[45%\]; nonreversible at both days: n=18 \[34%\]; [Figure 2](#f2-copd-11-2035){ref-type="fig"}). For ipratropium, at Day 10, 37 out of 54 (69%) patients had not changed their status from Day 1 (reversible at both days: n=25 \[46%\]; nonreversible at both days: n=12 \[22%\]). Patients who had a change in reversibility status tended to have FEV~1~ values clustered around the cut-off point used to define reversibility in this study ([Figure 2](#f2-copd-11-2035){ref-type="fig"}).

Discussion
==========

There was substantial variability of the FEV~1~ response to albuterol and ipratropium between patients. However, the mean within-patient difference in response to albuterol or ipratropium between Days 1 and 10 was relatively small: 47 mL and 27 mL, respectively. The bronchodilator response on Day 1 showed a good correlation with the response on Day 10 (*r*=0.64) which improved when the average response on subsequent occasions (Days 5--10) was used. Overall, these results suggest that the short-term repeatability of bronchodilator reversibility tests is generally good with stable responses being observed for most measurements. This was supported by the observation that the majority of patients did not change reversibility status between Day 1 and Day 10.

As might be expected, those patients who changed reversibility status in this study had values clustered around the binary cut-off point for reversibility. Previous studies have reported varying proportions of patients changing reversibility status, dependent on the criteria employed: 75%--79% by Hanania et al,[@b6-copd-11-2035] 38% and 52% by Calverley et al,[@b9-copd-11-2035] and 11% and 18% by Albert et al.[@b12-copd-11-2035] The different proportions reported across these studies could be due to a variety of factors, including the exclusion of patients with a higher magnitude of response,[@b9-copd-11-2035] the use of different cut-off points,[@b6-copd-11-2035],[@b9-copd-11-2035] the use of long-acting bronchodilators within the trials, and potential variability due to spirometric procedures between centers. In order to limit any spirometric measurement variations, this study was conducted in two centers specializing in spirometric measurements.

The issues with selecting a cut-off point can be illustrated with the data from a large study.[@b11-copd-11-2035] In this study, the mean response in FEV~1~ to albuterol was 164--177 mL but with SD values of 138--150 mL. This implied that 68% of patients (the percent of patients in any normal population who are within one SD of the mean[@b15-copd-11-2035]) were \<138--150 mL from the mean response.[@b11-copd-11-2035] It should therefore be no surprise that a large number of patients when retested would cross any arbitrary boundary (eg, 200 mL) near the mean value of this distribution due solely to the error inherent in the measurement of FEV~1~. Three previous studies that tested different cut-off points for bronchodilator response found that all criteria produced inconsistent results.[@b6-copd-11-2035],[@b9-copd-11-2035],[@b12-copd-11-2035] Consequently, the Global initiative of chronic Obstructive Lung Disease guidelines no longer recommend the use of reversibility for diagnosis of COPD or for prediction of future clinical outcomes.[@b2-copd-11-2035] As our study results support the findings of Calverley et al,[@b9-copd-11-2035] we suggest that future studies investigating the association of bronchodilator response with clinical outcomes should include bronchodilator response as a continuous, not dichotomized, variable.

This study had limitations. It was a post hoc analysis of data from an exploratory study, and as such should be treated with a degree of caution, but given that the correlations seen were statistically significant to a very high degree and other components of the analysis were purely descriptive, the findings warrant consideration and further investigation. A drawback of the study was its short duration. Long-term studies are required to determine if these findings are transferable over longer time frames.

Overall, we believe our study shows that bronchodilator responsiveness is a consistent variable within an individual patient over the short term, but highly variable between patients. With the measurement error inherent in spirometry in routine clinical practice, or even across multiple centers in large studies, we are cautious of suggesting that measuring a spirometric response may predict an individual's likelihood of achieving sustained benefit from bronchodilators. However, the results presented in this study do suggest that accurate measures of bronchodilation may be able to predict future response at the individual level over the short term.

Supplementary material
======================

###### 

Schematic diagram of the study design.

**Notes:** \*Drugs administered immediately after spirometry. S1: pre-dose spirometry; S2: spirometry 1 hour after drug 1; S3: spirometry 1 hour after drug 2.
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![Response to albuterol on Day 1 compared with Day 10.\
**Abbreviation:** FEV~1~, forced expiratory volume in 1 second.](copd-11-2035Fig1){#f1-copd-11-2035}

![Change in FEV~1~ on Day 1 for albuterol and ipratropium.\
**Notes:** Symbols demonstrate "reversibility" status on Day 10. Reversibility was defined as an increase in FEV~1~ of ≥12% and ≥200 mL following administration of albuterol or ipratropium. The square symbols represent patients whose reversibility status changed between Day 1 and Day 10.\
**Abbreviation:** FEV~1~, forced expiratory volume in 1 second.](copd-11-2035Fig2){#f2-copd-11-2035}

###### 

Mean changes and mean difference between absolute change in FEV~1~ on Day 1 and Day 10

                                                                                                         Day 1       Day 10
  ------------------------------------------------------------------------------------------------------ ----------- -----------
  Albuterol, n                                                                                           55          53
   Mean (n) change in FEV~1~ (SD) (mL)                                                                   261 (199)   237 (158)
   Mean (n) difference between Day 1 and Day 10 (SD) (mL)[\*](#tfn1-copd-11-2035){ref-type="table-fn"}               47 (112)
  Ipratropium, n                                                                                         55          54
   Mean (n) change in FEV~1~ (SD) (mL)                                                                   253 (180)   241 (163)
   Mean (n) difference between Day 1 and Day 10 (SD) (mL)[\*](#tfn1-copd-11-2035){ref-type="table-fn"}               27 (170)

**Note:**

The mean difference was calculated using the number of patients with data available on Day 10.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; SD, standard deviation.

###### 

Difference in FEV~1~ response to albuterol and ipratropium between Day 1 and Day 10, stratified by specific thresholds

  Difference between Day 1 and Day 10 (mL)   Albuterol, n=53[\*](#tfn3-copd-11-2035){ref-type="table-fn"}   Ipratropium, n=54[\*](#tfn3-copd-11-2035){ref-type="table-fn"}
  ------------------------------------------ -------------------------------------------------------------- ----------------------------------------------------------------
  \<100                                      31                                                             28
  ≥100 to \<150                              12                                                             8
  ≥150 to \<200                              4                                                              9
  ≥200                                       6                                                              9

**Notes:**

One patient completed the ipratropium study period but not the albuterol study period; therefore, n=53 for albuterol and n=54 for ipratropium.

**Abbreviation:** FEV~1~, forced expiratory volume in 1 second.
